TRIB: Trinity Biotech plc Company Buyout Price

Official company branding of trinitybiotech.com (TRIB)

This price chart illustrates the Enterprise Value of Trinity Biotech plc (TRIB), which currently stands at 137.39. The business generates revenue through the supply of diagnostic equipment, securing long-term income via the sale of high-cost reagents. Growth is driven by new insurance payouts in the US and the success of glucose monitoring systems. The brand's impeccable authority in infectious disease testing guarantees the loyalty of medical centers.

TRIB (Trinity Biotech plc) Total Company Value history from 11/23/2025 to 10/27/2026

TRIB (Trinity Biotech): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Performance Chart Trinity Biotech PLC|TRIB - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Trinity Biotech|TRIB - Enterprise Value
- book capitalization data:
Net Assets per Single Share Trinity Biotech|TRIB - Company Book Value|Market Cap to Net Assets Ratio trinitybiotech.com|TRIB - Company Total Assets
- debt and liquidity data:
Debt to Capital Trinity Biotech plc|TRIB - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Trinity Biotech PLC|TRIB - Company Aggregate Debts|Debts to Book Capitalization Trinity Biotech
Summary company analytics:Trinity Biotech plc (TRIB)
Original product of Trinity Biotech plc

To assess the long-term risks of Trinity Biotech plc (TRIB), it is essential to understand the actual value of the entire business. This metric aggregates market capitalization and debt while subtracting available cash, reflecting the actual acquisition price of the asset. By analyzing enterprise value trends, an investor can identify hidden imbalances between liabilities and equity. For Trinity Biotech plc (TRIB), such a metric confirms financial stability while scaling sales of diagnostic systems and consumables.

Competitor analysis

Value Adjusted for Debt and Cash Agilent Technologies, Inc. A|Enterprise Value DGX (Quest)|ILMN - Company Buyout Price|Exact Sciences (EXAS) - Enterprise Value|RVTY (revvity.com) - Total Company Value|Total Company Value BIO|Real Price to Acquire Entire Company Anbio Biotechnology Ltd|Sterigenics - Enterprise Value|Total Enterprise Value QuidelOrtho Inc. (QDEL)|OPK - Enterprise Value|Business Value CareDx Health CDNA|Maravai LifeSciences Holdings, Inc. - Enterprise Value|FLGT: Enterprise Value|Total Company Value Fluidigm|Cytek Corp (CTKB) - Business Value|OSUR (OraSure Technologies) - Enterprise Value|Enterprise Value XGN|Total Company Value MDxHealth (MDXH)|Total Company Value Lucid Diagnostics, Inc. LUCD|PRE: Real Price to Acquire Entire Company|Insight Molecular Diagnostics, Inc. - Total Enterprise Value|Total Company Value PRPH (ProPhase Labs, Inc.)|AIMD - Company Buyout Price|Co-Diagnostics - Enterprise Value|HSCS (Heart Test Laboratories, Inc.) - Company Buyout Price|BMRA: Total Company Value|Company Buyout Price Cardio Diagnostics Holdings, Inc. (CDIO)|Real Price to Acquire Entire Company Virax Biolabs Group|Aggregate Business Value BJDX (bluejaydx.com)|Total Company Value Aspira Women's Health Inc.|Value Adjusted for Debt and Cash Accelerate Diagnostics Inc. AXDX|Enterprise Value CNTG (Centogene)|ENZ: Company Buyout Price|Total Company Value fresh2.co|Genetic Technologies Limited (GENE) - Business Value|ME: Enterprise Value|Company Buyout Price Psychemedics Corp. (PMD)